Aldeyra Therapeutics (ALDX) said Thursday it has resubmitted a new drug application to the US Food and Drug Administration for topical ocular reproxalap, which is being developed as a treatment for signs and symptoms of dry eye disease.
Included in the resubmission were previously disclosed results from a completed trial requested by the FDA following a review of the prior NDA, the company said.
Price: 5.28, Change: -0.02, Percent Change: -0.38
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。